KVH INDUSTRIES INC \DE\ — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that KVH INDUSTRIES INC \DE\ filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Dec 31, 2015 | $9.62M | Mar 14, 2016 |
| FY2015 | Dec 31, 2014 | $9.27M | Mar 14, 2016 |
| FY2015 | Dec 31, 2013 | $5.65M | Mar 14, 2016 |
| FY2014 | Dec 31, 2012 | $10.55M | Mar 17, 2015 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $111.01M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $113.83M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $132.38M | Mar 10, 2025 |
| FY2023 | Sep 30, 2023 | $33.20M | Mar 15, 2024 |
| FY2023 | Jun 30, 2023 | $33.59M | Mar 15, 2024 |
| FY2023 | Mar 31, 2023 | $34.14M | Mar 15, 2024 |
| FY2023 | Dec 31, 2022 | $35.99M | Mar 15, 2024 |
| FY2023 | Sep 30, 2022 | $35.26M | Mar 15, 2024 |
| FY2023 | Jun 30, 2022 | $34.34M | Mar 15, 2024 |
| FY2023 | Mar 31, 2022 | $33.16M | Mar 15, 2024 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $160.09M | Mar 2, 2018 |
| FY2017 | Dec 31, 2016 | $176.12M | Mar 2, 2018 |
| FY2017 | Dec 31, 2015 | $184.63M | Mar 2, 2018 |
| FY2016 | Dec 31, 2014 | $172.59M | Mar 9, 2017 |
| FY2015 | Dec 31, 2013 | $162.29M | Mar 14, 2016 |
| FY2014 | Dec 31, 2012 | $137.11M | Mar 17, 2015 |
| FY2013 | Dec 31, 2011 | $112.54M | Mar 17, 2014 |
| FY2012 | Dec 31, 2010 | $112.24M | Apr 2, 2013 |
| FY2011 | Dec 31, 2009 | $89.06M | Mar 8, 2012 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2015 | $5.17M | Mar 9, 2017 |
| FY2016 | Sep 30, 2015 | $206.0K | Mar 9, 2017 |
| FY2016 | Jun 30, 2015 | ($258.0K) | Mar 9, 2017 |
| FY2016 | Mar 31, 2015 | ($1.91M) | Mar 9, 2017 |
| FY2015 | Dec 31, 2014 | $22.57M | Mar 14, 2016 |
| FY2015 | Sep 30, 2014 | $19.73M | Mar 14, 2016 |
| FY2015 | Jun 30, 2014 | $19.15M | Mar 14, 2016 |
| FY2015 | Mar 31, 2014 | $17.56M | Mar 14, 2016 |
| FY2014 | Dec 31, 2013 | $15.39M | Mar 17, 2015 |
| FY2015 | Sep 30, 2013 | $18.80M | Mar 14, 2016 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($7.38M) | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | ($11.05M) | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | ($15.42M) | Mar 10, 2025 |
| FY2023 | Sep 30, 2023 | ($4.37M) | Mar 15, 2024 |
| FY2023 | Jun 30, 2023 | $773.0K | Mar 15, 2024 |
| FY2023 | Mar 31, 2023 | $367.0K | Mar 15, 2024 |
| FY2023 | Dec 31, 2022 | $752.0K | Mar 15, 2024 |
| FY2023 | Sep 30, 2022 | $29.55M | Mar 15, 2024 |
| FY2023 | Jun 30, 2022 | ($1.53M) | Mar 15, 2024 |
| FY2023 | Mar 31, 2022 | ($4.74M) | Mar 15, 2024 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($11.17M) | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | ($11.88M) | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | ($17.35M) | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | ($5.73M) | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | ($19.60M) | Mar 16, 2023 |
| FY2020 | Dec 31, 2020 | ($11.35M) | Mar 3, 2021 |
| FY2020 | Sep 30, 2020 | ($503.0K) | Mar 3, 2021 |
| FY2020 | Jun 30, 2020 | ($3.44M) | Mar 3, 2021 |
| FY2020 | Mar 31, 2020 | ($7.65M) | Mar 3, 2021 |
| FY2020 | Dec 31, 2019 | ($3.33M) | Mar 3, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.46M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $8.44M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $9.40M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $10.37M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $11.07M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $15.80M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $15.93M | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | $14.95M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | $15.86M | Mar 1, 2019 |
| FY2018 | Dec 31, 2016 | $16.03M | Mar 1, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.11M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | ($13.17M) | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $2.53M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $8.89M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $2.91M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($3.08M) | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | ($14.17M) | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | $5.18M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | $11.53M | Mar 1, 2019 |
| FY2018 | Dec 31, 2016 | $18.70M | Mar 1, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.36M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $7.42M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $10.63M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $14.39M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $18.74M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $14.07M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $12.53M | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | $15.90M | Feb 28, 2020 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $151.50M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $155.08M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $172.63M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $196.25M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $168.79M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $183.59M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $199.39M | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | $187.65M | Feb 28, 2020 |
| FY2018 | Jan 1, 2018 | $205.61M | Mar 1, 2019 |
| FY2018 | Dec 31, 2017 | $196.24M | Mar 1, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.52M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $16.46M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $25.26M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $37.82M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $39.82M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $51.71M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $49.40M | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | $88.14M | Feb 28, 2020 |
| FY2018 | Jan 1, 2018 | $102.69M | Mar 1, 2019 |
| FY2018 | Dec 31, 2017 | $90.57M | Mar 1, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $130.98M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $138.63M | Mar 10, 2026 |
| FY2025 | Dec 31, 2023 | $147.37M | Mar 10, 2026 |
| FY2024 | Dec 31, 2022 | $158.44M | Mar 10, 2025 |
| FY2023 | Dec 31, 2021 | $130.83M | Mar 15, 2024 |
| FY2022 | Dec 31, 2020 | $131.88M | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | $149.99M | Mar 11, 2022 |
| FY2020 | Dec 31, 2018 | $99.52M | Mar 3, 2021 |
| FY2018 | Jan 1, 2018 | $102.92M | Mar 1, 2019 |
| FY2019 | Dec 31, 2017 | $105.67M | Feb 28, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $732.0K | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Mar 10, 2026 |
| FY2023 | Dec 31, 2023 | $0 | Mar 15, 2024 |
| FY2023 | Dec 31, 2022 | $5.31M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $6.57M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $6.59M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $15.41M | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | $15.03M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | $33.87M | Mar 1, 2019 |
| FY2018 | Dec 31, 2016 | $31.34M | Mar 1, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($20.14M) | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | ($12.75M) | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | ($1.70M) | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $13.72M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | ($12.17M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($2.40M) | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $19.54M | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | ($15.40M) | Feb 28, 2020 |
| FY2018 | Jan 1, 2018 | ($7.17M) | Mar 1, 2019 |
| FY2018 | Dec 31, 2017 | ($4.42M) | Mar 1, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $69.91M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $50.57M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $11.29M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $21.06M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $11.38M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $12.58M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $18.37M | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | $15.21M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | $34.60M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $26.42M | Mar 2, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $0 | Mar 11, 2022 |
| FY2021 | Dec 31, 2020 | $6.93M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $0 | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | $29.37M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | $47.05M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $58.05M | Mar 2, 2018 |
| FY2016 | Dec 31, 2015 | $64.69M | Mar 9, 2017 |
| FY2015 | Dec 31, 2014 | $70.88M | Mar 14, 2016 |
| FY2014 | Dec 31, 2013 | $38.37M | Mar 17, 2015 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | 1 | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 16, 2023 |
| FY2020 | Dec 31, 2020 | 0 | Mar 3, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Mar 3, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Mar 3, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Mar 3, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Mar 3, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | 1 | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 16, 2023 |
| FY2020 | Dec 31, 2020 | 0 | Mar 3, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Mar 3, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Mar 3, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Mar 3, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Mar 3, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 19.51M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | 19.78M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | 19.61M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | 19.20M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | 18.91M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | 18.43M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | 18.00M | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | 17.74M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | 17.13M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | 16.76M | Mar 2, 2018 |